๐ Eli Lilly $LLY pops +4% midday after Mounjaro & Zepbound crush Q2 expectations
Lilly smashed Q2 estimates โ revenue surged 47.7% year-over-year to $22.97B vs the $20.6B Wall Street expected, and EPS obliterated the consensus. The GLP-1 juggernaut raised its 2026 full-year sales guidance to $85โ$87B and tacked on $4.5B in new Indiana manufacturing capacity to keep up with demand. Not financial advice. Is there any ceiling in sight for weight-loss drug stocks?
โก 26 buzzing
467 views
๐ 0 subscribed